- Home
- BWLP vs NVCR Comparison
BWLP vs NVCR Comparison
Compare BWLP & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BWLP | NVCR |
|---|---|---|
| Founded | 1935 | 2000 |
| Country | Singapore | Switzerland |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | BWLP | NVCR |
|---|---|---|
| Price | $12.92 | $13.20 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $28.42 |
| AVG Volume (30 Days) | 425.6K | ★ 1.8M |
| Earning Date | 12-02-2025 | 10-30-2025 |
| Dividend Yield | ★ 10.19% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.14 | N/A |
| Revenue | ★ $3,693,482,000.00 | $642,269,000.00 |
| Revenue This Year | N/A | $9.75 |
| Revenue Next Year | $8.16 | $5.62 |
| P/E Ratio | $11.57 | ★ N/A |
| Revenue Growth | 2.54 | ★ 11.17 |
| 52 Week Low | $7.86 | $10.70 |
| 52 Week High | $16.60 | $31.17 |
Technical Indicators
Market Signals| Indicator | BWLP | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 58.70 | 55.90 |
| Support Level | $12.31 | $12.30 |
| Resistance Level | $12.65 | $13.64 |
| Average True Range (ATR) | 0.22 | 0.50 |
| MACD | 0.10 | 0.05 |
| Stochastic Oscillator | 83.57 | 55.69 |
Price Performance
Historical ComparisonAbout BWLP BW LPG Limited
BW LPG Ltd is an LPG shipping. It uses pioneering technology to power its vessels with cleaner-burning liquefied petroleum gas (LPG) and invest in R&D to take towards a zero-carbon future. The company is organized into two main segments: The shipping segment and the product services segment which buy and sell liquid petroleum gas and deliver it to customers. It generates the majority of its revenue from the shipping segment.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.